2025 Germany Cancer Gene Therapy Market Revenue Opportunities Report
Description
The 2025 Germany Cancer Gene Therapy Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Gene Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the cancer gene therapy market in Germany include Novartis AG, Gilead Sciences, Inc., Amgen Inc., and Bristol Myers Squibb. Novartis leads with its CAR-T cell therapy Kymriah, while Gilead Sciences markets Yescarta and Tecartus, both CAR-T therapies targeting various cancers. Amgen is involved in immuno-oncology and gene therapy development, and Bristol Myers Squibb offers CAR-T products like Breyanzi and Abecma. These companies benefit from Germany’s robust healthcare infrastructure and substantial investment in cell and gene therapy research, making Germany the largest cell and gene therapy market in Europe.
In addition to these multinational firms, German companies such as Medigene AG and innovative biotech spin-offs like Tcelltech GmbH and T-CURX GmbH also contribute significantly to the sector. Medigene focuses on T-cell therapies for cancer, whereas Tcelltech and T-CURX develop personalized adoptive cell therapies and CAR-T based immunotherapies, respectively. The German Cancer Research Center (DKFZ) supports these innovations, enhancing Germany’s position in advanced cancer gene therapy research and clinical trials. Collectively, these companies drive oncology-focused gene therapies with an emphasis on personalized and cellular immunotherapy approaches.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Gene Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the cancer gene therapy market in Germany include Novartis AG, Gilead Sciences, Inc., Amgen Inc., and Bristol Myers Squibb. Novartis leads with its CAR-T cell therapy Kymriah, while Gilead Sciences markets Yescarta and Tecartus, both CAR-T therapies targeting various cancers. Amgen is involved in immuno-oncology and gene therapy development, and Bristol Myers Squibb offers CAR-T products like Breyanzi and Abecma. These companies benefit from Germany’s robust healthcare infrastructure and substantial investment in cell and gene therapy research, making Germany the largest cell and gene therapy market in Europe.
In addition to these multinational firms, German companies such as Medigene AG and innovative biotech spin-offs like Tcelltech GmbH and T-CURX GmbH also contribute significantly to the sector. Medigene focuses on T-cell therapies for cancer, whereas Tcelltech and T-CURX develop personalized adoptive cell therapies and CAR-T based immunotherapies, respectively. The German Cancer Research Center (DKFZ) supports these innovations, enhancing Germany’s position in advanced cancer gene therapy research and clinical trials. Collectively, these companies drive oncology-focused gene therapies with an emphasis on personalized and cellular immunotherapy approaches.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
